Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

SIMPLE SUMMARY: Although the incorporation of immune checkpoint inhibitors (ICIs) in melanoma treatment has significantly improved prognosis for patients with advanced disease, a substantial proportion of patients have limited clinical benefit from ICIs’ administration. Except for the well-studied P...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziogas, Dimitrios C., Theocharopoulos, Charalampos, Lialios, Panagiotis-Petros, Foteinou, Dimitra, Koumprentziotis, Ioannis-Alexios, Xynos, Georgios, Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216291/
https://www.ncbi.nlm.nih.gov/pubmed/37345056
http://dx.doi.org/10.3390/cancers15102718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216291/
https://www.ncbi.nlm.nih.gov/pubmed/37345056
http://dx.doi.org/10.3390/cancers15102718

Ejemplares similares